First-ever CRISPR drug, made by two Boston companies, is approved in the US
By Rowan Walrath In a first for the Nobel Prize-winning gene-editing technology, a CRISPR-based drug has been approved in the U.S. The Food and Drug Administration gave the green light Friday to exa-cel, a drug made by two Boston-based companies, Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) and CRISPR Therapeutics Inc. (Nasdaq: CRSP). It will be marketed under […]